🚀 VC round data is live in beta, check it out!
Kaken Pharmaceutical Valuation Multiples
Discover revenue and EBITDA valuation multiples for Kaken Pharmaceutical and similar public comparables like Strides Pharma, Evommune, Pacira BioSciences, HK inno.N and more.
Kaken Pharmaceutical Overview
About Kaken Pharmaceutical
Kaken Pharmaceutical Co Ltd is a specialty and generic drug manufacturing company. The company organizes its segments between pharmaceutical and real estate activities. The pharmaceutical segment consists of pharmaceutical drugs, medical devices, and agrochemicals. In the real estate segment, the majority of revenue is generated through commercial facility rental fees. Sales in Japan constitute more than 90% of revenue. Kaken considers merger and acquisition investment to be a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
Founded
1948
HQ
Employees
1.6K
Website
Financials (LTM)
EV
$729M
Kaken Pharmaceutical Financials
Kaken Pharmaceutical reported last 12-month revenue of $529M and EBITDA of $35M.
In the same LTM period, Kaken Pharmaceutical generated $293M in gross profit, $35M in EBITDA, and $18M in net income.
Revenue (LTM)
Kaken Pharmaceutical P&L
In the most recent fiscal year, Kaken Pharmaceutical reported revenue of $636M and EBITDA of $160M.
Kaken Pharmaceutical expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $529M | XXX | $636M | XXX | XXX | XXX |
| Gross Profit | $293M | XXX | $368M | XXX | XXX | XXX |
| Gross Margin | 55% | XXX | 58% | XXX | XXX | XXX |
| EBITDA | $35M | XXX | $160M | XXX | XXX | XXX |
| EBITDA Margin | 7% | XXX | 25% | XXX | XXX | XXX |
| EBIT Margin | 4% | XXX | 22% | XXX | XXX | XXX |
| Net Profit | $18M | XXX | $94M | XXX | XXX | XXX |
| Net Margin | 3% | XXX | 15% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Kaken Pharmaceutical Stock Performance
Kaken Pharmaceutical has current market cap of $993M, and enterprise value of $729M.
Market Cap Evolution
Kaken Pharmaceutical's stock price is $26.23.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $729M | $993M | -1.2% | XXX | XXX | XXX | $2.49 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialKaken Pharmaceutical Valuation Multiples
Kaken Pharmaceutical trades at 1.4x EV/Revenue multiple, and 20.8x EV/EBITDA.
EV / Revenue (LTM)
Kaken Pharmaceutical Financial Valuation Multiples
As of April 18, 2026, Kaken Pharmaceutical has market cap of $993M and EV of $729M.
Equity research analysts estimate Kaken Pharmaceutical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Kaken Pharmaceutical has a P/E ratio of 54.3x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $993M | XXX | $993M | XXX | XXX | XXX |
| EV (current) | $729M | XXX | $729M | XXX | XXX | XXX |
| EV/Revenue | 1.4x | XXX | 1.1x | XXX | XXX | XXX |
| EV/EBITDA | 20.8x | XXX | 4.6x | XXX | XXX | XXX |
| EV/EBIT | 38.1x | XXX | 5.1x | XXX | XXX | XXX |
| EV/Gross Profit | 2.5x | XXX | 2.0x | XXX | XXX | XXX |
| P/E | 54.3x | XXX | 10.5x | XXX | XXX | XXX |
| EV/FCF | 8.8x | XXX | 4.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Kaken Pharmaceutical Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Kaken Pharmaceutical Margins & Growth Rates
Kaken Pharmaceutical's revenue in the last 12 month declined by (9%).
Kaken Pharmaceutical's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.1M for the same period.
Kaken Pharmaceutical's rule of 40 is (4%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Kaken Pharmaceutical's rule of X is (19%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Kaken Pharmaceutical Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | (9%) | XXX | (16%) | XXX | XXX | XXX |
| EBITDA Margin | 7% | XXX | 25% | XXX | XXX | XXX |
| EBITDA Growth | (23%) | XXX | (78%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | (4%) | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | (19%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 18% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 37% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Kaken Pharmaceutical Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Kaken Pharmaceutical | XXX | XXX | XXX | XXX | XXX | XXX |
| Strides Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Evommune | XXX | XXX | XXX | XXX | XXX | XXX |
| Pacira BioSciences | XXX | XXX | XXX | XXX | XXX | XXX |
| HK inno.N | XXX | XXX | XXX | XXX | XXX | XXX |
| Ventyx Biosciences | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Kaken Pharmaceutical M&A Activity
Kaken Pharmaceutical acquired XXX companies to date.
Last acquisition by Kaken Pharmaceutical was on XXXXXXXX, XXXXX. Kaken Pharmaceutical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Kaken Pharmaceutical
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialKaken Pharmaceutical Investment Activity
Kaken Pharmaceutical invested in XXX companies to date.
Kaken Pharmaceutical made its latest investment on XXXXXXXX, XXXXX. Kaken Pharmaceutical invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Kaken Pharmaceutical
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Kaken Pharmaceutical
| When was Kaken Pharmaceutical founded? | Kaken Pharmaceutical was founded in 1948. |
| Where is Kaken Pharmaceutical headquartered? | Kaken Pharmaceutical is headquartered in Japan. |
| How many employees does Kaken Pharmaceutical have? | As of today, Kaken Pharmaceutical has over 1K employees. |
| Is Kaken Pharmaceutical publicly listed? | Yes, Kaken Pharmaceutical is a public company listed on Tokyo Stock Exchange. |
| What is the stock symbol of Kaken Pharmaceutical? | Kaken Pharmaceutical trades under 4521 ticker. |
| When did Kaken Pharmaceutical go public? | Kaken Pharmaceutical went public in 1961. |
| Who are competitors of Kaken Pharmaceutical? | Kaken Pharmaceutical main competitors are Strides Pharma, Evommune, Pacira BioSciences, HK inno.N. |
| What is the current market cap of Kaken Pharmaceutical? | Kaken Pharmaceutical's current market cap is $993M. |
| What is the current revenue of Kaken Pharmaceutical? | Kaken Pharmaceutical's last 12 months revenue is $529M. |
| What is the current revenue growth of Kaken Pharmaceutical? | Kaken Pharmaceutical revenue growth (NTM/LTM) is (9%). |
| What is the current EV/Revenue multiple of Kaken Pharmaceutical? | Current revenue multiple of Kaken Pharmaceutical is 1.4x. |
| Is Kaken Pharmaceutical profitable? | Yes, Kaken Pharmaceutical is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Kaken Pharmaceutical? | Kaken Pharmaceutical's last 12 months EBITDA is $35M. |
| What is Kaken Pharmaceutical's EBITDA margin? | Kaken Pharmaceutical's last 12 months EBITDA margin is 7%. |
| What is the current EV/EBITDA multiple of Kaken Pharmaceutical? | Current EBITDA multiple of Kaken Pharmaceutical is 20.8x. |
| What is the current FCF of Kaken Pharmaceutical? | Kaken Pharmaceutical's last 12 months FCF is $83M. |
| What is Kaken Pharmaceutical's FCF margin? | Kaken Pharmaceutical's last 12 months FCF margin is 16%. |
| What is the current EV/FCF multiple of Kaken Pharmaceutical? | Current FCF multiple of Kaken Pharmaceutical is 8.8x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.